{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T23:06:03Z","timestamp":1791155163586,"version":"4.1.0"},"reference-count":161,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.1038\/ncpneph0444","type":"journal-article","created":{"date-parts":[[2007,3,27]],"date-time":"2007-03-27T17:22:39Z","timestamp":1175016159000},"page":"208-221","source":"Crossref","is-referenced-by-count":118,"title":["Mechanisms of Disease: the tissue kallikrein\u2013kinin system in hypertension and vascular remodeling"],"prefix":"10.1038","volume":"3","author":[{"given":"Paolo","family":"Madeddu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Costanza","family":"Emanueli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"El-Dahr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BFncpneph0444_CR1","first-page":"1","volume":"44","author":"KD Bhoola","year":"1992","unstructured":"Bhoola KD et al. (1992) Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev 44: 1\u201380","journal-title":"Pharmacol Rev"},{"key":"BFncpneph0444_CR2","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1161\/01.HYP.16.4.436","volume":"16","author":"H Nolly","year":"1990","unstructured":"Nolly H et al. (1990) A kallikrein-like enzyme in blood vessels of one-kidney, one clip hypertensive rats. Hypertension 16: 436\u2013440","journal-title":"Hypertension"},{"key":"BFncpneph0444_CR3","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1161\/01.HYP.23.6.899","volume":"23","author":"P Madeddu","year":"1994","unstructured":"Madeddu P et al. (1994) A kallikrein-like enzyme in the aorta of normotensive and hypertensive rats. Hypertension 23: 899\u2013902","journal-title":"Hypertension"},{"key":"BFncpneph0444_CR4","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1093\/ajh\/6.5.344","volume":"6","author":"P Madeddu","year":"1993","unstructured":"Madeddu P et al. (1993) A kallikrein-like enzyme in human vascular tissue. Am J Hypertens 6: 344\u2013348","journal-title":"Am J Hypertens"},{"key":"BFncpneph0444_CR5","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1515\/BC.1999.168","volume":"380","author":"M Kemme","year":"1999","unstructured":"Kemme M et al. (1999) Identification of immunoreactive tissue prokallikrein on the surface membrane of human neutrophils. Biol Chem 380: 1321\u20131328","journal-title":"Biol Chem"},{"key":"BFncpneph0444_CR6","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/S0167-4889(02)00393-2","volume":"1593","author":"K Yayama","year":"2003","unstructured":"Yayama K et al. (2003) Tissue kallikrein is synthesized and secreted by human vascular endothelial cells. Biochim Biophys Acta 1593: 231\u2013238","journal-title":"Biochim Biophys Acta"},{"issue":"Suppl 1","key":"BFncpneph0444_CR7","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1097\/00005344-200312001-00012","volume":"42","author":"Y Yano","year":"2003","unstructured":"Yano Y et al. (2003) Immunohistochemical distributions of the tissue kallikrein-kinin system in ischemic and non-ischemic mouse heart. J Cardiovasc Pharmacol 42 (Suppl 1): S49\u2013S53","journal-title":"J Cardiovasc Pharmacol"},{"key":"BFncpneph0444_CR8","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1515\/BC.2000.135","volume":"381","author":"J Plendl","year":"2000","unstructured":"Plendl J et al. (2000) Expression of tissue kallikrein and kinin receptors in angiogenic microvascular endothelial cells. Biol Chem 381: 1103\u20131115","journal-title":"Biol Chem"},{"key":"BFncpneph0444_CR9","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S0163-7258(00)00080-2","volume":"88","author":"R Mahabeer","year":"2000","unstructured":"Mahabeer R and Bhoola KD (2000) Kallikrein and kinin receptor genes. Pharmacol Ther 88: 77\u201389","journal-title":"Pharmacol Ther"},{"key":"BFncpneph0444_CR10","doi-asserted-by":"publisher","first-page":"40371","DOI":"10.1074\/jbc.M005691200","volume":"275","author":"VC Chen","year":"2000","unstructured":"Chen VC et al. (2000) A positively charged loop on the surface of kallistatin functions to enhance tissue kallikrein inhibition by acting as a secondary binding site for kallikrein. J Biol Chem 275: 40371\u201340377","journal-title":"J Biol Chem"},{"key":"BFncpneph0444_CR11","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1046\/j.1440-1681.2001.03564.x","volume":"28","author":"DJ Campbell","year":"2001","unstructured":"Campbell DJ (2001) The kallikrein-kinin system in humans. Clin Exp Pharmacol Physiol 28: 1060\u20131065","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"BFncpneph0444_CR12","doi-asserted-by":"publisher","first-page":"799","DOI":"10.3109\/10641969409078026","volume":"16","author":"N Ura","year":"1994","unstructured":"Ura N et al. (1994) The role of kinins and atrial natriuretic peptide on the renal effects of neutral endopeptidase inhibitor in rats. Clin Exp Hypertens 16: 799\u2013808","journal-title":"Clin Exp Hypertens"},{"key":"BFncpneph0444_CR13","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1161\/01.CIR.94.3.517","volume":"94","author":"AA Hasan","year":"1996","unstructured":"Hasan AA et al. (1996) Bradykinin and its metabolite, Arg-Pro-Pro-Gly-Phe, are selective inhibitors of alpha-thrombin-induced platelet activation. Circulation 94: 517\u2013528","journal-title":"Circulation"},{"key":"BFncpneph0444_CR14","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/nrd1522","volume":"3","author":"F Marceau","year":"2004","unstructured":"Marceau F and Regoli D (2004) Bradykinin receptor ligands: therapeutic perspectives. Nat Rev Drug Discov 3: 845\u2013852","journal-title":"Nat Rev Drug Discov"},{"key":"BFncpneph0444_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1124\/pr.57.1.2","volume":"57","author":"LM Leeb-Lundberg","year":"2005","unstructured":"Leeb-Lundberg LM et al. (2005) International union of pharmacology. XLV: classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev 57: 27\u201377","journal-title":"Pharmacol Rev"},{"key":"BFncpneph0444_CR16","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1161\/01.RES.76.4.522","volume":"76","author":"I Fleming","year":"1995","unstructured":"Fleming I et al. (1995) Calcium signaling in endothelial cells involves activation of tyrosine kinases and leads to activation of mitogen-activated protein kinases. Circ Res 76: 522\u2013529","journal-title":"Circ Res"},{"key":"BFncpneph0444_CR17","doi-asserted-by":"publisher","first-page":"11009","DOI":"10.1074\/jbc.271.18.11009","volume":"271","author":"I Fleming","year":"1996","unstructured":"Fleming I et al. (1996) Interdependence of calcium signaling and protein tyrosine phosphorylation in human endothelial cells. J Biol Chem 271: 11009\u201311015","journal-title":"J Biol Chem"},{"key":"BFncpneph0444_CR18","first-page":"F728","volume":"274","author":"MA Lal","year":"1998","unstructured":"Lal MA et al. (1998) A role for PKC epsilon and MAP kinase in bradykinin-induced arachidonic acid release in rabbit CCD cells. Am J Physiol 274: F728\u2013735","journal-title":"Am J Physiol"},{"key":"BFncpneph0444_CR19","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3109\/07853899509002586","volume":"27","author":"R Busse","year":"1995","unstructured":"Busse R and Fleming I (1995) Regulation and functional consequences of endothelial nitric oxide formation. Ann Med 27: 331\u2013340","journal-title":"Ann Med"},{"key":"BFncpneph0444_CR20","doi-asserted-by":"publisher","first-page":"E3","DOI":"10.1016\/S0002-9149(99)80496-2","volume":"76","author":"PM Vanhoutte","year":"1995","unstructured":"Vanhoutte PM et al. (1995) Endothelium-derived relaxing factors and converting enzyme inhibition. Am J Cardiol 76: E3\u2013E12","journal-title":"Am J Cardiol"},{"key":"BFncpneph0444_CR21","doi-asserted-by":"publisher","first-page":"16587","DOI":"10.1074\/jbc.M100229200","volume":"276","author":"MB Harris","year":"2001","unstructured":"Harris MB et al. (2001) Reciprocal phosphorylation and regulation of endothelial nitric-oxide synthase in response to bradykinin stimulation. J Biol Chem 276: 16587\u201316591","journal-title":"J Biol Chem"},{"key":"BFncpneph0444_CR22","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1161\/01.CIR.0000142051.36244.83","volume":"110","author":"C Emanueli","year":"2004","unstructured":"Emanueli C et al. (2004) Akt\/protein kinase B and endothelial nitric oxide synthase mediate muscular neovascularization induced by tissue kallikrein gene transfer. Circulation 110: 1638\u20131644","journal-title":"Circulation"},{"key":"BFncpneph0444_CR23","doi-asserted-by":"publisher","first-page":"24025","DOI":"10.1074\/jbc.273.37.24025","volume":"273","author":"H Ju","year":"1998","unstructured":"Ju H et al. (1998) Inhibitory interactions of the bradykinin B2 receptor with endothelial nitric-oxide synthase. J Biol Chem 273: 24025\u201324029","journal-title":"J Biol Chem"},{"key":"BFncpneph0444_CR24","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.cardiores.2005.12.014","volume":"69","author":"O Feron","year":"2006","unstructured":"Feron O and Balligand JL (2006) Caveolins and the regulation of endothelial nitric oxide synthase in the heart. Cardiovasc Res 69: 788\u2013797","journal-title":"Cardiovasc Res"},{"key":"BFncpneph0444_CR25","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/S1567-5769(02)00185-6","volume":"2","author":"RC Venema","year":"2002","unstructured":"Venema RC (2002) Post-translational mechanisms of endothelial nitric oxide synthase regulation by bradykinin. Int Immunopharmacol 2: 1755\u20131762","journal-title":"Int Immunopharmacol"},{"key":"BFncpneph0444_CR26","first-page":"H1074","volume":"253","author":"LJ Ignarro","year":"1987","unstructured":"Ignarro LJ et al. (1987) Mechanisms of endothelium-dependent vascular smooth muscle relaxation elicited by bradykinin and VIP. Am J Physiol 253: H1074\u2013H1082","journal-title":"Am J Physiol"},{"key":"BFncpneph0444_CR27","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/sj.bjp.0705747","volume":"142","author":"WW Batenburg","year":"2004","unstructured":"Batenburg WW et al. (2004) Bradykinin-induced relaxation of coronary microarteries: S-nitrosothiols as EDHF? Br J Pharmacol 142: 125\u2013135","journal-title":"Br J Pharmacol"},{"key":"BFncpneph0444_CR28","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1161\/01.CIR.100.13.1400","volume":"100","author":"S Taddei","year":"1999","unstructured":"Taddei S et al. (1999) Vasodilation to bradykinin is mediated by an ouabain-sensitive pathway as a compensatory mechanism for impaired nitric oxide availability in essential hypertensive patients. Circulation 100: 1400\u20131405","journal-title":"Circulation"},{"key":"BFncpneph0444_CR29","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1124\/mol.58.4.828","volume":"58","author":"C Hecquet","year":"2000","unstructured":"Hecquet C et al. (2000) Human bradykinin B2 receptor is activated by kallikrein and other serine proteases. Mol Pharmacol 58: 828\u2013836","journal-title":"Mol Pharmacol"},{"key":"BFncpneph0444_CR30","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/BF02737658","volume":"16","author":"F Marceau","year":"1998","unstructured":"Marceau F and Bachvarov DR (1998) Kinin receptors. Clin Rev Allergy Immunol 16: 385\u2013401","journal-title":"Clin Rev Allergy Immunol"},{"key":"BFncpneph0444_CR31","first-page":"128","volume":"50","author":"SA Mathis","year":"1996","unstructured":"Mathis SA et al. (1996) B1 and B2 kinin receptors mediate distinct patterns of intracellular Ca2+ signaling in single cultured vascular smooth muscle cells. Mol Pharmacol 50: 128\u2013139","journal-title":"Mol Pharmacol"},{"key":"BFncpneph0444_CR32","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/j.1365-2125.1994.tb04360.x","volume":"38","author":"JR Cockcroft","year":"1994","unstructured":"Cockcroft JR et al. (1994) Inhibition of bradykinin-induced vasodilation in human forearm vasculature by icatibant, a potent B2-receptor antagonist. Br J Clin Pharmacol 38: 317\u2013321","journal-title":"Br J Clin Pharmacol"},{"key":"BFncpneph0444_CR33","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1161\/01.CIR.91.6.1732","volume":"91","author":"JA Panza","year":"1995","unstructured":"Panza JA et al. (1995) Impaired endothelium-dependent vasodilation in patients with essential hypertension: evidence that nitric oxide abnormality is not localized to a single signal transduction pathway. Circulation 91: 1732\u20131738","journal-title":"Circulation"},{"key":"BFncpneph0444_CR34","doi-asserted-by":"publisher","first-page":"3424","DOI":"10.1161\/01.CIR.92.12.3424","volume":"92","author":"P Groves","year":"1995","unstructured":"Groves P et al. (1995) Role of endogenous bradykinin in human coronary vasomotor control. Circulation 92: 3424\u20133430","journal-title":"Circulation"},{"key":"BFncpneph0444_CR35","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1161\/01.CIR.92.2.183","volume":"92","author":"T Kuga","year":"1995","unstructured":"Kuga T et al. (1995) Bradykinin-induced vasodilation is impaired at the atherosclerotic site but is preserved at the spastic site of human coronary arteries in vivo. Circulation 92: 183\u2013189","journal-title":"Circulation"},{"key":"BFncpneph0444_CR36","first-page":"F87","volume":"248","author":"JP Granger","year":"1985","unstructured":"Granger JP and Hall JE (1985) Acute and chronic actions of bradykinin on renal function and arterial pressure. Am J Physiol 248: F87\u2013F92","journal-title":"Am J Physiol"},{"key":"BFncpneph0444_CR37","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1161\/01.CIR.0000153269.07762.3B","volume":"111","author":"DJ Campbell","year":"2005","unstructured":"Campbell DJ et al. (2005) Losartan increases bradykinin levels in hypertensive humans. Circulation 111: 315\u2013320","journal-title":"Circulation"},{"key":"BFncpneph0444_CR38","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1097\/00004872-198710000-00012","volume":"5","author":"P Madeddu","year":"1987","unstructured":"Madeddu P et al. (1987) The effects of aprotinin, a kallikrein inhibitor, on renin release and urinary sodium excretion in mild essential hypertensives. J Hypertens 5: 581\u2013586","journal-title":"J Hypertens"},{"key":"BFncpneph0444_CR39","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1172\/JCI119502","volume":"100","author":"J Chao","year":"1997","unstructured":"Chao J et al. (1997) Kallistatin is a potent new vasodilator. J Clin Invest 100: 11\u201317","journal-title":"J Clin Invest"},{"key":"BFncpneph0444_CR40","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/0196-9781(85)90033-6","volume":"6","author":"RJ Vavrek","year":"1985","unstructured":"Vavrek RJ and Stewart JM (1985) Competitive antagonists of bradykinin. Peptides 6: 161\u2013164","journal-title":"Peptides"},{"key":"BFncpneph0444_CR41","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/j.1476-5381.1991.tb12169.x","volume":"102","author":"F Lembeck","year":"1991","unstructured":"Lembeck F et al. (1991) New, long-acting, potent bradykinin antagonists. Br J Pharmacol 102: 297\u2013304","journal-title":"Br J Pharmacol"},{"key":"BFncpneph0444_CR42","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/sj.bjp.0703012","volume":"129","author":"GM Burgess","year":"2000","unstructured":"Burgess GM et al. (2000) Bradyzide, a potent non-peptide B2 bradykinin receptor antagonist with long-lasting oral activity in animal models of inflammatory hyperalgesia. Br J Pharmacol 129: 77\u201386","journal-title":"Br J Pharmacol"},{"key":"BFncpneph0444_CR43","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1021\/jm991155o","volume":"43","author":"EK Dziadulewicz","year":"2000","unstructured":"Dziadulewicz EK et al. (2000) 1-(2-Nitrophenyl)thiosemicarbazides: a novel class of potent, orally active non-peptide antagonist for the bradykinin B2 receptor. J Med Chem 43: 769\u2013771","journal-title":"J Med Chem"},{"key":"BFncpneph0444_CR44","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/sj.bjp.0700966","volume":"120","author":"T Griesbacher","year":"1997","unstructured":"Griesbacher T and Legat FJ (1997) Effects of FR173657, a non-peptide B2 antagonist, on kinin-induced hypotension, visceral and peripheral oedema formation and bronchoconstriction. Br J Pharmacol 120: 933\u2013939","journal-title":"Br J Pharmacol"},{"key":"BFncpneph0444_CR45","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S0162-3109(99)00128-9","volume":"43","author":"D Pruneau","year":"1999","unstructured":"Pruneau D et al. (1999) Pharmacological profile of LF 16-0687, a new potent non-peptide bradykinin B2 receptor antagonist. Immunopharmacology 43: 187\u2013194","journal-title":"Immunopharmacology"},{"key":"BFncpneph0444_CR46","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1161\/01.HYP.11.3.239","volume":"11","author":"LF Carbonell","year":"1988","unstructured":"Carbonell LF et al. (1988) Effect of a kinin antagonist on the acute antihypertensive activity of enalaprilat in severe hypertension. Hypertension 11: 239\u2013243","journal-title":"Hypertension"},{"key":"BFncpneph0444_CR47","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1161\/01.HYP.25.3.453","volume":"25","author":"P Madeddu","year":"1995","unstructured":"Madeddu P et al. (1995) Early blockade of bradykinin B2-receptors alters the adult cardiovascular phenotype in rats. Hypertension 25: 453\u2013459","journal-title":"Hypertension"},{"key":"BFncpneph0444_CR48","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1161\/01.HYP.36.1.132","volume":"36","author":"IB Squire","year":"2000","unstructured":"Squire IB et al. (2000) Bradykinin B2 receptor antagonism attenuates blood pressure response to acute angiotensin-converting enzyme inhibition in normal men. Hypertension 36: 132\u2013136","journal-title":"Hypertension"},{"key":"BFncpneph0444_CR49","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1161\/01.HYP.23.5.646","volume":"23","author":"P Madeddu","year":"1994","unstructured":"Madeddu P et al. (1994) Chronic inhibition of bradykinin B2-receptors enhances the slow vasopressor response to angiotensin II. Hypertension 23: 646\u2013652","journal-title":"Hypertension"},{"key":"BFncpneph0444_CR50","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1161\/01.HYP.21.6.980","volume":"21","author":"P Madeddu","year":"1993","unstructured":"Madeddu P et al. (1993) Bradykinin B2-receptor blockade facilitates deoxycorticosterone-salt hypertension. Hypertension 21: 980\u2013984","journal-title":"Hypertension"},{"key":"BFncpneph0444_CR51","doi-asserted-by":"publisher","first-page":"E268","DOI":"10.1152\/ajpendo.00382.2005","volume":"291","author":"A Duka","year":"2006","unstructured":"Duka A et al. (2006) Role of bradykinin B1 and B2 receptors in normal blood pressure regulation. Am J Physiol Endocrinol Metab 291: E268\u2013E274","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"BFncpneph0444_CR52","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1161\/01.HYP.0000228997.88162.a8","volume":"48","author":"PM Abadir","year":"2006","unstructured":"Abadir PM et al. (2006) Angiotensin II type 2 receptor-bradykinin B2 receptor functional heterodimerization. Hypertension 48: 316\u2013322","journal-title":"Hypertension"},{"key":"BFncpneph0444_CR53","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1385\/JMN:26:2-3:185","volume":"26","author":"S AbdAlla","year":"2005","unstructured":"AbdAlla S et al. (2005) Mesangial AT1\/B2 receptor heterodimers contribute to angiotensin II hyperresponsiveness in experimental hypertension. J Mol Neurosci 26: 185\u2013192","journal-title":"J Mol Neurosci"},{"key":"BFncpneph0444_CR54","first-page":"226","volume":"6","author":"SC Hunt","year":"1993","unstructured":"Hunt SC et al. (1993) Environmental determinants of urinary kallikrein excretion. Am J Hypertens 6: 226\u2013233","journal-title":"Am J Hypertens"},{"key":"BFncpneph0444_CR55","first-page":"25","volume":"47","author":"W Linz","year":"1995","unstructured":"Linz W et al. (1995) Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 47: 25\u201349","journal-title":"Pharmacol Rev"},{"issue":"Suppl 1","key":"BFncpneph0444_CR56","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1097\/01.hjh.0000220405.38622.23","volume":"24","author":"U Landmesser","year":"2006","unstructured":"Landmesser U and Drexler H (2006) Effect of angiotensin II type 1 receptor antagonism on endothelial function: role of bradykinin and nitric oxide. J Hypertens 24 (Suppl 1): S39\u2013S43","journal-title":"J Hypertens"},{"key":"BFncpneph0444_CR57","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1056\/NEJM199810293391804","volume":"339","author":"JV Gainer","year":"1998","unstructured":"Gainer JV et al. (1998) Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 339: 1285\u20131292","journal-title":"N Engl J Med"},{"key":"BFncpneph0444_CR58","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1161\/01.HYP.17.6.1038","volume":"17","author":"FJ Fenoy","year":"1991","unstructured":"Fenoy FJ et al. (1991) Effect of an angiotensin II and a kinin receptor antagonist on the renal hemodynamic response to captopril. Hypertension 17: 1038\u20131044","journal-title":"Hypertension"},{"key":"BFncpneph0444_CR59","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1681\/ASN.V10112272","volume":"10","author":"H Matsuda","year":"1999","unstructured":"Matsuda H et al. (1999) Zonal heterogeneity in action of angiotensin-converting enzyme inhibitor on renal microcirculation: role of intrarenal bradykinin. J Am Soc Nephrol 10: 2272\u20132282","journal-title":"J Am Soc Nephrol"},{"key":"BFncpneph0444_CR60","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1161\/01.HYP.0000118053.42262.71","volume":"43","author":"H Matsuda","year":"2004","unstructured":"Matsuda H et al. (2004) Role of endothelium-derived hyperpolarizing factor in ACE inhibitor-induced renal vasodilation in vivo. Hypertension 43: 603\u2013609","journal-title":"Hypertension"},{"key":"BFncpneph0444_CR61","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1161\/01.RES.86.5.589","volume":"86","author":"J Tornel","year":"2000","unstructured":"Tornel J et al. (2000) Role of kinins in the control of renal papillary blood flow, pressure natriuresis, and arterial pressure. Circ Res 86: 589\u2013595","journal-title":"Circ Res"},{"key":"BFncpneph0444_CR62","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1161\/hh1001.090759","volume":"88","author":"XP Yang","year":"2001","unstructured":"Yang XP et al. (2001) Diminished cardioprotective response to inhibition of angiotensin-converting enzyme and angiotensin II type 1 receptor in B2 kinin receptor gene knockout mice. Circ Res 88: 1072\u20131079","journal-title":"Circ Res"},{"key":"BFncpneph0444_CR63","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1097\/00004872-200018020-00014","volume":"18","author":"C Tsch\u00f6pe","year":"2000","unstructured":"Tsch\u00f6pe C et al. (2000) Myocardial bradykinin B2-receptor expression at different time points after induction of myocardial infarction. J Hypertens 18: 223\u2013228","journal-title":"J Hypertens"},{"key":"BFncpneph0444_CR64","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1038\/sj.bjp.0703239","volume":"129","author":"C Tsch\u00f6pe","year":"2000","unstructured":"Tsch\u00f6pe C et al. (2000) Upregulation of bradykinin B1-receptor expression after myocardial infarction. Br J Pharmacol 129: 1537\u20131538","journal-title":"Br J Pharmacol"},{"key":"BFncpneph0444_CR65","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1161\/hc4301.098252","volume":"104","author":"FN Witherow","year":"2001","unstructured":"Witherow FN et al. (2001) Bradykinin contributes to the vasodilator effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure. Circulation 104: 2177\u20132181","journal-title":"Circulation"},{"key":"BFncpneph0444_CR66","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1161\/01.CIR.100.3.268","volume":"100","author":"AP Davie","year":"1999","unstructured":"Davie AP et al. (1999) Role of bradykinin in the vasodilator effects of losartan and enalapril in patients with heart failure. Circulation 100: 268\u2013273","journal-title":"Circulation"},{"key":"BFncpneph0444_CR67","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1161\/01.HYP.31.6.1299","volume":"31","author":"C Emanueli","year":"1998","unstructured":"Emanueli C et al. (1998) Acute ACE inhibition causes plasma extravasation in mice that is mediated by bradykinin and substance P. Hypertension 31: 1299\u20131304","journal-title":"Hypertension"},{"key":"BFncpneph0444_CR68","first-page":"M288","volume":"39","author":"N Koga","year":"1993","unstructured":"Koga N et al. (1993) Anaphylactoid reactions and bradykinin generation in patients treated with LDL-apheresis and an ACE inhibitor. ASAIO J 39: M288\u2013M291","journal-title":"ASAIO J"},{"key":"BFncpneph0444_CR69","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/S0140-6736(94)92978-5","volume":"343","author":"DC Davidson","year":"1994","unstructured":"Davidson DC et al. (1994) Prevention with icatibant of anaphylactoid reactions to ACE inhibitor during LDL apheresis. Lancet 343: 1575","journal-title":"Lancet"},{"key":"BFncpneph0444_CR70","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1038\/nm0796-814","volume":"2","author":"AJ Fox","year":"1996","unstructured":"Fox AJ et al. (1996) Bradykinin-evoked sensitization of airway sensory nerves: a mechanism for ACE-inhibitor cough. Nat Med 2: 814\u2013817","journal-title":"Nat Med"},{"key":"BFncpneph0444_CR71","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1124\/jpet.102.038067","volume":"303","author":"G Molinaro","year":"2002","unstructured":"Molinaro G et al. (2002) Angiotensin-converting enzyme inhibitor-associated angioedema is characterized by a slower degradation of des-arginine9-bradykinin. J Pharmacol Exp Ther 303: 232\u2013237","journal-title":"J Pharmacol Exp Ther"},{"key":"BFncpneph0444_CR72","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.clpt.2005.08.010","volume":"78","author":"M Pretorius","year":"2005","unstructured":"Pretorius M et al. (2005) A pilot study indicating that bradykinin B2 receptor antagonism attenuates protamine-related hypotension after cardiopulmonary bypass. Clin Pharmacol Ther 78: 477\u2013485","journal-title":"Clin Pharmacol Ther"},{"key":"BFncpneph0444_CR73","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1161\/01.HYP.15.4.407","volume":"15","author":"P Madeddu","year":"1990","unstructured":"Madeddu P et al. (1990) Brain kinins are responsible for the pressor effect of intracerebroventricular captopril in spontaneously hypertensive rats. Hypertension 15: 407\u2013412","journal-title":"Hypertension"},{"key":"BFncpneph0444_CR74","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1038\/sj.bjp.0702527","volume":"126","author":"C Emanueli","year":"1999","unstructured":"Emanueli C et al. (1999) The bradykinin B1 receptor and the central regulation of blood pressure in spontaneously hypertensive rats. Br J Pharmacol 126: 1769\u20131776","journal-title":"Br J Pharmacol"},{"key":"BFncpneph0444_CR75","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1161\/01.HYP.28.6.980","volume":"28","author":"P Madeddu","year":"1996","unstructured":"Madeddu P et al. (1996) Antisense inhibition of the brain kallikrein-kinin system. Hypertension 28: 980\u2013987","journal-title":"Hypertension"},{"key":"BFncpneph0444_CR76","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1097\/00004872-198911000-00003","volume":"7","author":"C Woodley-Miller","year":"1989","unstructured":"Woodley-Miller C et al. (1989) Restriction fragment length polymorphisms mapped in spontaneously hypertensive rats using kallikrein probes. J Hypertens 7: 865\u2013871","journal-title":"J Hypertens"},{"issue":"Suppl","key":"BFncpneph0444_CR77","first-page":"S60","volume":"26","author":"I Gavras","year":"1988","unstructured":"Gavras I and Gavras H (1988) Anti-hormones and blood pressure: bradykinin antagonists in blood pressure regulation. Kidney Int 26 (Suppl): S60\u2013S62","journal-title":"Kidney Int"},{"key":"BFncpneph0444_CR78","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1161\/01.HYP.29.1.471","volume":"29","author":"P Madeddu","year":"1997","unstructured":"Madeddu P et al. (1997) Kallikrein-kinin system and blood pressure sensitivity to salt. Hypertension 29: 471\u2013477","journal-title":"Hypertension"},{"key":"BFncpneph0444_CR79","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1046\/j.1523-1755.2001.00738.x","volume":"59","author":"P Madeddu","year":"2001","unstructured":"Madeddu P et al. (2001) Renal phenotype of low kallikrein rats. Kidney Int 59: 2233\u20132242","journal-title":"Kidney Int"},{"key":"BFncpneph0444_CR80","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/BF02737655","volume":"16","author":"HS Margolius","year":"1998","unstructured":"Margolius HS (1998) Tissue kallikreins structure, regulation, and participation in mammalian physiology and disease. Clin Rev Allergy Immunol 16: 337\u2013349","journal-title":"Clin Rev Allergy Immunol"},{"key":"BFncpneph0444_CR81","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1161\/01.CIR.58.5.908","volume":"58","author":"SH Zinner","year":"1978","unstructured":"Zinner SH et al. (1978) Stability of blood pressure rank and urinary kallikrein concentration in childhood: an eight-year follow-up. Circulation 58: 908\u2013915","journal-title":"Circulation"},{"key":"BFncpneph0444_CR82","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/j.1399-0004.1993.tb03879.x","volume":"44","author":"KE Berge","year":"1993","unstructured":"Berge KE and Berg K (1993) No effect of TaqI polymorphism at the human renal kallikrein (KLK1) locus on normal blood pressure level or variability. Clin Genet 44: 196\u2013202","journal-title":"Clin Genet"},{"key":"BFncpneph0444_CR83","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/j.1440-1681.1996.tb02780.x","volume":"23","author":"LR Friend","year":"1996","unstructured":"Friend LR et al. (1996) Examination of the role of nitric oxide synthase and renal kallikrein as candidate genes for essential hypertension. Clin Exp Pharmacol Physiol 23: 564\u2013566","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"BFncpneph0444_CR84","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1161\/01.HYP.31.4.906","volume":"31","author":"H Yu","year":"1998","unstructured":"Yu H et al. (1998) Identification of human plasma kallikrein gene polymorphisms and evaluation of their role in end-stage renal disease. Hypertension 31: 906\u2013911","journal-title":"Hypertension"},{"key":"BFncpneph0444_CR85","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/sj.jhh.1001875","volume":"19","author":"H Hua","year":"2005","unstructured":"Hua H et al. (2005) Relationship between the regulatory region polymorphism of human tissue kallikrein gene and essential hypertension. J Hum Hypertens 19: 715\u2013721","journal-title":"J Hum Hypertens"},{"key":"BFncpneph0444_CR86","doi-asserted-by":"publisher","first-page":"S319","DOI":"10.1093\/ajh\/6.11.319S","volume":"6","author":"RR Williams","year":"1993","unstructured":"Williams RR et al. (1993) Genetic basis of familial dyslipidemia and hypertension: 15-year results from Utah. Am J Hypertens 6: S319\u2013S327","journal-title":"Am J Hypertens"},{"issue":"Suppl 1","key":"BFncpneph0444_CR87","doi-asserted-by":"publisher","first-page":"S69","DOI":"10.1161\/01.HYP.17.1_Suppl.I69","volume":"17","author":"RR Williams","year":"1991","unstructured":"Williams RR et al. (1991) Genetic traits related to hypertension and electrolyte metabolism. Hypertension 17 (Suppl 1): S69\u2013S73","journal-title":"Hypertension"},{"key":"BFncpneph0444_CR88","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1161\/01.HYP.13.1.3","volume":"13","author":"TD Berry","year":"1989","unstructured":"Berry TD et al. (1989) A gene for high urinary kallikrein may protect against hypertension in Utah kindreds. Hypertension 13: 3\u20138","journal-title":"Hypertension"},{"key":"BFncpneph0444_CR89","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1681\/ASN.V134968","volume":"13","author":"R Slim","year":"2002","unstructured":"Slim R et al. (2002) Loss-of-function polymorphism of the human kallikrein gene with reduced urinary kallikrein activity. J Am Soc Nephrol 13: 968\u2013976","journal-title":"J Am Soc Nephrol"},{"key":"BFncpneph0444_CR90","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1172\/JCI200523669","volume":"115","author":"M Azizi","year":"2005","unstructured":"Azizi M et al. (2005) Arterial and renal consequences of partial genetic deficiency in tissue kallikrein activity in humans. J Clin Invest 115: 780\u2013787","journal-title":"J Clin Invest"},{"key":"BFncpneph0444_CR91","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1097\/01.hjh.0000244943.34546.40","volume":"24","author":"GP Rossi","year":"2006","unstructured":"Rossi GP et al. (2006) Tissue kallikrein gene polymorphisms induce no change in endothelium-dependent or independent vasodilation in hypertensive and normotensive subjects. J Hypertens 24: 1955\u20131963","journal-title":"J Hypertens"},{"key":"BFncpneph0444_CR92","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1161\/01.HYP.24.1.111","volume":"24","author":"M Majima","year":"1994","unstructured":"Majima M et al. (1994) Hypertension induced by a nonpressor dose of angiotensin II in kininogen-deficient rats. Hypertension 24: 111\u2013119","journal-title":"Hypertension"},{"key":"BFncpneph0444_CR93","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1161\/01.HYP.17.2.242","volume":"17","author":"M Pravenec","year":"1991","unstructured":"Pravenec M et al. (1991) Cosegregation of blood pressure with a kallikrein gene family polymorphism. Hypertension 17: 242\u2013246","journal-title":"Hypertension"},{"key":"BFncpneph0444_CR94","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1172\/JCI114844","volume":"86","author":"B Rigat","year":"1990","unstructured":"Rigat B et al. (1990) An insertion\/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 86: 1343\u20131346","journal-title":"J Clin Invest"},{"key":"BFncpneph0444_CR95","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1161\/01.CIR.92.6.1387","volume":"92","author":"AH Danser","year":"1995","unstructured":"Danser AH et al. (1995) Angiotensin-converting enzyme in the human heart: effect of the deletion\/insertion polymorphism. Circulation 92: 1387\u20131388","journal-title":"Circulation"},{"key":"BFncpneph0444_CR96","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1161\/01.CIR.103.2.226","volume":"103","author":"SG Myerson","year":"2001","unstructured":"Myerson SG et al. (2001) Left ventricular hypertrophy with exercise and ACE gene insertion\/deletion polymorphism: a randomized controlled trial with losartan. Circulation 103: 226\u2013230","journal-title":"Circulation"},{"key":"BFncpneph0444_CR97","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1161\/01.HYP.37.2.293","volume":"37","author":"GP Rossi","year":"2001","unstructured":"Rossi GP et al. (2001) Exclusion of the ACE D\/I gene polymorphism as a determinant of endothelial dysfunction. Hypertension 37: 293\u2013300","journal-title":"Hypertension"},{"key":"BFncpneph0444_CR98","first-page":"134","volume":"99","author":"CC Lung","year":"1997","unstructured":"Lung CC et al. (1997) Analysis of an exon 1 polymorphism of the B2 bradykinin receptor gene and its transcript in normal subjects and patients with C1 inhibitor deficiency. J Allergy Clin Immunol 99: 134\u2013146","journal-title":"J Allergy Clin Immunol"},{"key":"BFncpneph0444_CR99","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/S0140-6736(01)06273-0","volume":"358","author":"D Brull","year":"2001","unstructured":"Brull D et al. (2001) Bradykinin B2BKR receptor polymorphism and left-ventricular growth response. Lancet 358: 1155\u20131156","journal-title":"Lancet"},{"key":"BFncpneph0444_CR100","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/00004872-200501000-00013","volume":"23","author":"J Cui","year":"2005","unstructured":"Cui J et al. (2005) Sequence variation of bradykinin receptors B1 and B2 and association with hypertension. J Hypertens 23: 55\u201362","journal-title":"J Hypertens"},{"key":"BFncpneph0444_CR101","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1016\/S0195-668X(03)00441-X","volume":"24","author":"SS Dhamrait","year":"2003","unstructured":"Dhamrait SS et al. (2003) Variation in bradykinin receptor genes increases the cardiovascular risk associated with hypertension. Eur Heart J 24: 1672\u20131680","journal-title":"Eur Heart J"},{"key":"BFncpneph0444_CR102","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1515\/BC.2006.017","volume":"387","author":"JB Pesquero","year":"2006","unstructured":"Pesquero JB and Bader M (2006) Genetically altered animal models in the kallikrein-kinin system. Biol Chem 387: 119\u2013126","journal-title":"Biol Chem"},{"key":"BFncpneph0444_CR103","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1161\/01.HYP.23.2.236","volume":"23","author":"J Wang","year":"1994","unstructured":"Wang J et al. (1994) Human tissue kallikrein induces hypotension in transgenic mice. Hypertension 23: 236\u2013243","journal-title":"Hypertension"},{"key":"BFncpneph0444_CR104","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1161\/01.HYP.27.3.491","volume":"27","author":"J Chao","year":"1996","unstructured":"Chao J and Chao L (1996) Functional analysis of human tissue kallikrein in transgenic mouse models. Hypertension 27: 491\u2013494","journal-title":"Hypertension"},{"key":"BFncpneph0444_CR105","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1096\/fj.99-1010fje","volume":"14","author":"JA Silva Jr","year":"2000","unstructured":"Silva JA, Jr et al. (2000) Reduced cardiac hypertrophy and altered blood pressure control in transgenic rats with the human tissue kallikrein gene. FASEB J 14: 1858\u20131860","journal-title":"FASEB J"},{"key":"BFncpneph0444_CR106","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1161\/01.HYP.29.1.488","volume":"29","author":"DZ Wang","year":"1997","unstructured":"Wang DZ et al. (1997) Hypotension in transgenic mice overexpressing human bradykinin B2 receptor. Hypertension 29: 488\u2013493","journal-title":"Hypertension"},{"key":"BFncpneph0444_CR107","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1096\/fj.99-1011fje","volume":"14","author":"YM Pinto","year":"2000","unstructured":"Pinto YM et al. (2000) Increased kallikrein expression protects against cardiac ischemia. FASEB J 14: 1861\u20131863","journal-title":"FASEB J"},{"key":"BFncpneph0444_CR108","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1172\/JCI0215493","volume":"110","author":"JP Schanstra","year":"2002","unstructured":"Schanstra JP et al. (2002) In vivo bradykinin B2 receptor activation reduces renal fibrosis. J Clin Invest 110: 371\u2013379","journal-title":"J Clin Invest"},{"key":"BFncpneph0444_CR109","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1096\/fj.03-0736com","volume":"18","author":"C Tschope","year":"2004","unstructured":"Tschope C et al. (2004) Prevention of cardiac fibrosis and left ventricular dysfunction in diabetic cardiomyopathy in rats by transgenic expression of the human tissue kallikrein gene. FASEB J 18: 828\u2013835","journal-title":"FASEB J"},{"key":"BFncpneph0444_CR110","doi-asserted-by":"publisher","first-page":"F484","DOI":"10.1152\/ajprenal.2000.278.3.F484","volume":"278","author":"D Wang","year":"2000","unstructured":"Wang D et al. (2000) Enhanced renal function in bradykinin B2 receptor transgenic mice. Am J Physiol Renal Physiol 278: F484\u2013F491","journal-title":"Am J Physiol Renal Physiol"},{"key":"BFncpneph0444_CR111","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1073\/pnas.051619598","volume":"98","author":"P Meneton","year":"2001","unstructured":"Meneton P et al. (2001) Cardiovascular abnormalities with normal blood pressure in tissue kallikrein-deficient mice. Proc Natl Acad Sci USA 98: 2634\u20132639","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFncpneph0444_CR112","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1172\/JCI200214211","volume":"109","author":"ED Han","year":"2002","unstructured":"Han ED et al. (2002) Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest 109: 1057\u20131063","journal-title":"J Clin Invest"},{"key":"BFncpneph0444_CR113","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1161\/01.RES.88.6.593","volume":"88","author":"S Bergaya","year":"2001","unstructured":"Bergaya S et al. (2001) Decreased flow-dependent dilation in carotid arteries of tissue kallikrein-knockout mice. Circ Res 88: 593\u2013599","journal-title":"Circ Res"},{"key":"BFncpneph0444_CR114","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1161\/01.ATV.0000090672.07568.60","volume":"23","author":"RH Hilgers","year":"2003","unstructured":"Hilgers RH et al. (2003) Uterine artery structural and functional changes during pregnancy in tissue kallikrein-deficient mice. Arterioscler Thromb Vasc Biol 23: 1826\u20131832","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"BFncpneph0444_CR115","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1097\/00004872-200404000-00017","volume":"22","author":"S Bergaya","year":"2004","unstructured":"Bergaya S et al. (2004) Role of tissue kallikrein in response to flow in mouse resistance arteries. J Hypertens 22: 745\u2013750","journal-title":"J Hypertens"},{"key":"BFncpneph0444_CR116","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1096\/fj.04-3508fje","volume":"19","author":"V Griol-Charhbili","year":"2005","unstructured":"Griol-Charhbili V et al. (2005) Role of tissue kallikrein in the cardioprotective effects of ischemic and pharmacological preconditioning in myocardial ischemia. FASEB J 19: 1172\u20131174","journal-title":"FASEB J"},{"key":"BFncpneph0444_CR117","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1161\/01.HYP.0000021747.43346.95","volume":"40","author":"F Trabold","year":"2002","unstructured":"Trabold F et al. (2002) Cardiovascular phenotypes of kinin B2 receptor- and tissue kallikrein-deficient mice. Hypertension 40: 90\u201395","journal-title":"Hypertension"},{"key":"BFncpneph0444_CR118","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1161\/01.HYP.29.1.150","volume":"29","author":"JH Krege","year":"1997","unstructured":"Krege JH et al. (1997) Angiotensin-converting enzyme gene mutations, blood pressures, and cardiovascular homeostasis. Hypertension 29: 150\u2013157","journal-title":"Hypertension"},{"key":"BFncpneph0444_CR119","doi-asserted-by":"publisher","first-page":"13330","DOI":"10.1073\/pnas.231476798","volume":"98","author":"W Huang","year":"2001","unstructured":"Huang W et al. (2001) Genetically increased angiotensin I-converting enzyme level and renal complications in the diabetic mouse. Proc Natl Acad Sci USA 98: 13330\u201313334","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFncpneph0444_CR120","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1161\/01.HYP.30.1.128","volume":"30","author":"B Tian","year":"1997","unstructured":"Tian B et al. (1997) Blood pressures and cardiovascular homeostasis in mice having reduced or absent angiotensin-converting enzyme gene function. Hypertension 30: 128\u2013133","journal-title":"Hypertension"},{"key":"BFncpneph0444_CR121","doi-asserted-by":"publisher","first-page":"H1969","DOI":"10.1152\/ajpheart.00010.2003","volume":"284","author":"HD Xiao","year":"2003","unstructured":"Xiao HD et al. (2003) Role of bradykinin in angiotensin-converting enzyme knockout mice. Am J Physiol Heart Circ Physiol 284: H1969\u2013H1977","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"BFncpneph0444_CR122","doi-asserted-by":"publisher","first-page":"3570","DOI":"10.1161\/01.CIR.96.10.3570","volume":"96","author":"P Madeddu","year":"1997","unstructured":"Madeddu P et al. (1997) Cardiovascular phenotype of a mouse strain with disruption of bradykinin B2-receptor gene. Circulation 96: 3570\u20133578","journal-title":"Circulation"},{"key":"BFncpneph0444_CR123","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1161\/hy1201.096574","volume":"38","author":"I Duka","year":"2001","unstructured":"Duka I et al. (2001) Role of the B2 receptor of bradykinin in insulin sensitivity. Hypertension 38: 1355\u20131360","journal-title":"Hypertension"},{"key":"BFncpneph0444_CR124","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/nm0897-904","volume":"3","author":"B Lu","year":"1997","unstructured":"Lu B et al. (1997) The control of microvascular permeability and blood pressure by neutral endopeptidase. Nat Med 3: 904\u2013907","journal-title":"Nat Med"},{"key":"BFncpneph0444_CR125","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1006\/bbrc.1996.1076","volume":"224","author":"ME Alfie","year":"1996","unstructured":"Alfie ME et al. (1996) Salt-sensitive hypertension in bradykinin B2 receptor knockout mice. Biochem Biophys Res Commun 224: 625\u2013630","journal-title":"Biochem Biophys Res Commun"},{"key":"BFncpneph0444_CR126","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/S0895-7061(99)00073-4","volume":"12","author":"C Emanueli","year":"1999","unstructured":"Emanueli C and Madeddu P (1999) Role of the kallikrein-kinin system in the maturation of cardiovascular phenotype. Am J Hypertens 12: 988\u2013999","journal-title":"Am J Hypertens"},{"key":"BFncpneph0444_CR127","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1161\/01.HYP.0000064180.55222.DF","volume":"41","author":"R Maestri","year":"2003","unstructured":"Maestri R et al. (2003) Cardiac hypertrophy and microvascular deficit in kinin B2 receptor knockout mice. Hypertension 41: 1151\u20131155","journal-title":"Hypertension"},{"key":"BFncpneph0444_CR128","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1161\/01.HYP.37.6.1473","volume":"37","author":"AF Milia","year":"2001","unstructured":"Milia AF et al. (2001) Normal blood pressure and renal function in mice lacking the bradykinin B2 receptor. Hypertension 37: 1473\u20131479","journal-title":"Hypertension"},{"key":"BFncpneph0444_CR129","doi-asserted-by":"publisher","first-page":"H1904","DOI":"10.1152\/ajpheart.01150.2002","volume":"284","author":"JP Schanstra","year":"2003","unstructured":"Schanstra JP et al. (2003) Decreased renal NO excretion and reduced glomerular tuft area in mice lacking the bradykinin B2 receptor. Am J Physiol Heart Circ Physiol 284: H1904\u2013H1908","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"BFncpneph0444_CR130","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1097\/01.ASN.0000017902.77985.84","volume":"13","author":"Q Wang","year":"2002","unstructured":"Wang Q et al. (2002) Blood pressure, cardiac, and renal responses to salt and deoxycorticosterone acetate in mice: role of renin genes. J Am Soc Nephrol 13: 1509\u20131516","journal-title":"J Am Soc Nephrol"},{"key":"BFncpneph0444_CR131","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1161\/01.HYP.35.1.391","volume":"35","author":"P Madeddu","year":"2000","unstructured":"Madeddu P et al. (2000) Angiotensin II type 1 receptor blockade prevents cardiac remodeling in bradykinin B2 receptor knockout mice. Hypertension 35: 391\u2013396","journal-title":"Hypertension"},{"key":"BFncpneph0444_CR132","doi-asserted-by":"publisher","first-page":"F538","DOI":"10.1152\/ajprenal.00340.2002","volume":"284","author":"LM Harrison-Bernard","year":"2003","unstructured":"Harrison-Bernard LM et al. (2003) Renal segmental microvascular responses to ANG II in AT1A receptor null mice. Am J Physiol Renal Physiol 284: F538\u2013F545","journal-title":"Am J Physiol Renal Physiol"},{"key":"BFncpneph0444_CR133","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1161\/01.HYP.31.6.1278","volume":"31","author":"C Emanueli","year":"1998","unstructured":"Emanueli C et al. (1998) Enhanced blood pressure sensitivity to deoxycorticosterone in mice with disruption of bradykinin B2 receptor gene. Hypertension 31: 1278\u20131283","journal-title":"Hypertension"},{"key":"BFncpneph0444_CR134","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1161\/01.HYP.32.3.503","volume":"32","author":"P Madeddu","year":"1998","unstructured":"Madeddu P et al. (1998) Renovascular hypertension in bradykinin B2-receptor knockout mice. Hypertension 32: 503\u2013509","journal-title":"Hypertension"},{"key":"BFncpneph0444_CR135","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1161\/01.HYP.34.2.176","volume":"34","author":"L Cervenka","year":"1999","unstructured":"Cervenka L et al. (1999) Early onset salt-sensitive hypertension in bradykinin B2 receptor null mice. Hypertension 34: 176\u2013180","journal-title":"Hypertension"},{"key":"BFncpneph0444_CR136","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1097\/00004872-200308000-00018","volume":"21","author":"L Cervenka","year":"2003","unstructured":"Cervenka L et al. (2003) Genetic inactivation of the B2 receptor in mice worsens two-kidney, one-clip hypertension: role of NO and the AT2 receptor. J Hypertens 21: 1531\u20131538","journal-title":"J Hypertens"},{"key":"BFncpneph0444_CR137","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1161\/01.HYP.0000214867.35632.0e","volume":"47","author":"CF Xia","year":"2006","unstructured":"Xia CF et al. (2006) Postischemic brain injury is exacerbated in mice lacking the kinin B2 receptor. Hypertension 47: 752\u2013761","journal-title":"Hypertension"},{"key":"BFncpneph0444_CR138","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1182\/blood-2006-01-0094","volume":"108","author":"Z Shariat-Madar","year":"2006","unstructured":"Shariat-Madar Z et al. (2006) Bradykinin B2 receptor knockout mice are protected from thrombosis by increased nitric oxide and prostacyclin. Blood 108: 192\u2013199","journal-title":"Blood"},{"key":"BFncpneph0444_CR139","doi-asserted-by":"publisher","first-page":"8140","DOI":"10.1073\/pnas.120035997","volume":"97","author":"JB Pesquero","year":"2000","unstructured":"Pesquero JB et al. (2000) Hypoalgesia and altered inflammatory responses in mice lacking kinin B1 receptors. Proc Natl Acad Sci USA 97: 8140\u20138145","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFncpneph0444_CR140","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/S0165-6147(00)01761-2","volume":"22","author":"C Emanueli","year":"2001","unstructured":"Emanueli C and Madeddu P (2001) Targeting kinin receptors for the treatment of tissue ischaemia. Trends Pharmacol Sci 22: 478\u2013484","journal-title":"Trends Pharmacol Sci"},{"key":"BFncpneph0444_CR141","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1161\/01.HYP.0000153322.04859.81","volume":"45","author":"J Xu","year":"2005","unstructured":"Xu J et al. (2005) Role of the B1 kinin receptor in the regulation of cardiac function and remodeling after myocardial infarction. Hypertension 45: 747\u2013753","journal-title":"Hypertension"},{"key":"BFncpneph0444_CR142","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1515\/BC.2006.004","volume":"387","author":"D Bachvarov","year":"2006","unstructured":"Bachvarov D et al. (2006) Renal gene expression profiling using kinin B1 and B2 receptor knockout mice reveals comparable modulation of functionally related genes. Biol Chem 387: 15\u201322","journal-title":"Biol Chem"},{"key":"BFncpneph0444_CR143","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1161\/01.HYP.25.4.715","volume":"25","author":"W Xiong","year":"1995","unstructured":"Xiong W et al. (1995) Muscle delivery of human kallikrein gene reduces blood pressure in hypertensive rats. Hypertension 25: 715\u2013719","journal-title":"Hypertension"},{"key":"BFncpneph0444_CR144","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1172\/JCI117847","volume":"95","author":"C Wang","year":"1995","unstructured":"Wang C et al. (1995) Direct gene delivery of human tissue kallikrein reduces blood pressure in spontaneously hypertensive rats. J Clin Invest 95: 1710\u20131716","journal-title":"J Clin Invest"},{"key":"BFncpneph0444_CR145","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1089\/hum.1997.8.15-1753","volume":"8","author":"L Jin","year":"1997","unstructured":"Jin L et al. (1997) Gene therapy in hypertension: adenovirus-mediated kallikrein gene delivery in hypertensive rats. Hum Gene Ther 8: 1753\u20131761","journal-title":"Hum Gene Ther"},{"key":"BFncpneph0444_CR146","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1046\/j.1523-1755.1998.00104.x","volume":"54","author":"J Chao","year":"1998","unstructured":"Chao J et al. (1998) Adenovirus-mediated kallikrein gene delivery reverses salt-induced renal injury in Dahl salt-sensitive rats. Kidney Int 54: 1250\u20131260","journal-title":"Kidney Int"},{"key":"BFncpneph0444_CR147","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1161\/01.HYP.31.5.1104","volume":"31","author":"K Yayama","year":"1998","unstructured":"Yayama K et al. (1998) Kallikrein gene delivery attenuates hypertension and cardiac hypertrophy and enhances renal function in Goldblatt hypertensive rats. Hypertension 31: 1104\u20131110","journal-title":"Hypertension"},{"key":"BFncpneph0444_CR148","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1046\/j.1523-1755.2000.00219.x","volume":"58","author":"WC Wolf","year":"2000","unstructured":"Wolf WC et al. (2000) Human tissue kallikrein gene delivery attenuates hypertension, renal injury, and cardiac remodeling in chronic renal failure. Kidney Int 58: 730\u2013739","journal-title":"Kidney Int"},{"key":"BFncpneph0444_CR149","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1161\/01.STR.30.9.1925","volume":"30","author":"JJ Zhang","year":"1999","unstructured":"Zhang JJ et al. (1999) Adenovirus-mediated kallikrein gene delivery reduces aortic thickening and stroke-induced death rate in Dahl salt-sensitive rats. Stroke 30: 1925\u20131931","journal-title":"Stroke"},{"key":"BFncpneph0444_CR150","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1161\/01.HYP.0000110905.29389.e5","volume":"43","author":"CF Xia","year":"2004","unstructured":"Xia CF et al. (2004) Kallikrein gene transfer protects against ischemic stroke by promoting glial cell migration and inhibiting apoptosis. Hypertension 43: 452\u2013459","journal-title":"Hypertension"},{"key":"BFncpneph0444_CR151","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1089\/hum.2006.17.206","volume":"17","author":"CF Xia","year":"2006","unstructured":"Xia CF et al. (2006) Kallikrein protects against ischemic stroke by inhibiting apoptosis and inflammation and promoting angiogenesis and neurogenesis. Hum Gene Ther 17: 206\u2013219","journal-title":"Hum Gene Ther"},{"key":"BFncpneph0444_CR152","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1089\/hum.2006.17.545","volume":"17","author":"G Bledsoe","year":"2006","unstructured":"Bledsoe G et al. (2006) Reversal of renal fibrosis, inflammation, and glomerular hypertrophy by kallikrein gene delivery. Hum Gene Ther 17: 545\u2013555","journal-title":"Hum Gene Ther"},{"key":"BFncpneph0444_CR153","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1161\/01.HYP.38.1.136","volume":"38","author":"C Emanueli","year":"2001","unstructured":"Emanueli C et al. (2001) Rescue of impaired angiogenesis in spontaneously hypertensive rats by intramuscular human tissue kallikrein gene transfer. Hypertension 38: 136\u2013141","journal-title":"Hypertension"},{"key":"BFncpneph0444_CR154","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2217\/17460751.1.2.235","volume":"1","author":"F Spillman","year":"2006","unstructured":"Spillman F et al. (2006) Regional and global protective effects of tissue kallikrein gene delivery to the peri-infarct myocardium. Regen Med 1: 235\u2013254","journal-title":"Regen Med"},{"key":"BFncpneph0444_CR155","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1161\/01.CIR.103.1.125","volume":"103","author":"C Emanueli","year":"2001","unstructured":"Emanueli C et al. (2001) Local delivery of human tissue kallikrein gene accelerates spontaneous angiogenesis in mouse model of hindlimb ischemia. Circulation 103: 125\u2013132","journal-title":"Circulation"},{"key":"BFncpneph0444_CR156","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1161\/01.ATV.20.11.2379","volume":"20","author":"C Emanueli","year":"2000","unstructured":"Emanueli C et al. (2000) Adenovirus-mediated human tissue kallikrein gene delivery induces angiogenesis in normoperfused skeletal muscle. Arterioscler Thromb Vasc Biol 20: 2379\u20132385","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"BFncpneph0444_CR157","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1161\/01.CIR.0000142051.36244.83","volume":"110","author":"C Emanueli","year":"2004","unstructured":"Emanueli C et al. (2004) Akt\/protein kinase B and endothelial nitric oxide synthase mediate muscular neovascularization induced by tissue kallikrein gene transfer. Circulation 110: 1638\u20131644","journal-title":"Circulation"},{"key":"BFncpneph0444_CR158","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1096\/fj.00-0503fje","volume":"15","author":"A Parenti","year":"2001","unstructured":"Parenti A et al. (2001) The bradykinin\/B1 receptor promotes angiogenesis by up-regulation of endogenous FGF-2 in endothelium via the nitric oxide synthase pathway. FASEB J 15: 1487\u20131489","journal-title":"FASEB J"},{"key":"BFncpneph0444_CR159","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1161\/01.ATV.0000149377.90852.d8","volume":"25","author":"TG Ebrahimian","year":"2005","unstructured":"Ebrahimian TG et al. (2005) Dual effect of angiotensin-converting enzyme inhibition on angiogenesis in type 1 diabetic mice. Arterioscler Thromb Vasc Biol 25: 65\u201370","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"BFncpneph0444_CR160","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/sj.bjp.0704461","volume":"135","author":"C Emanueli","year":"2002","unstructured":"Emanueli C et al. (2002) Angiotensin AT1 receptor signalling modulates reparative angiogenesis induced by limb ischaemia. Br J Pharmacol 135: 87\u201392","journal-title":"Br J Pharmacol"},{"key":"BFncpneph0444_CR161","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1515\/BC.2001.182","volume":"382","author":"J Dedio","year":"2001","unstructured":"Dedio J et al. (2001) Tissue kallikrein KLK1 is expressed de novo in endothelial cells and mediates relaxation of human umbilical veins. Biol Chem 382: 1483\u20131490","journal-title":"Biol Chem"}],"container-title":["Nature Clinical Practice Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncpneph0444.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpneph0444","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/ncpneph0444","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/ncpneph0444.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T20:17:17Z","timestamp":1684441037000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncpneph0444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":161,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["BFncpneph0444"],"URL":"https:\/\/doi.org\/10.1038\/ncpneph0444","relation":{},"ISSN":["1745-8323","1745-8331"],"issn-type":[{"value":"1745-8323","type":"print"},{"value":"1745-8331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,4]]}}}